ArticleLiver international : official journal of the International Association for the Study of the Liver2023
A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06446609 (Understanding the Natural History and Impact of Itching), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding the Natural History and Impact of Itching (Pruritus) in Patients With Drug-induced Liver Injury (DILI)
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- The contemporary epidemiology, causes, and management of drug-induced liver injury.Hepatology communications · 2026Review
- Common Causes of Drug-Induced Liver Injury in 2025.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Review
- Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug-Induced Liver Injury Network Experience.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- CYP2E1 and CYP2D6 in Anti-Tuberculosis Drug-Induced Liver Injury: Mechanisms, Epigenetic Regulation, and Translational Implications.Clinical and translational science · 2026Review
- Aspartate aminotransferase and model for end-stage liver disease reliably predict mortality in drug-induced liver injury.Scientific reports · 2026Article
- Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries.Journal for immunotherapy of cancer · 2026Article
- A pharmacist-led framework for antibiotic-associated liver injury: from pharmacovigilance signals to bedside surveillance with the updated RUCAM and susceptibility markers.Frontiers in pharmacology · 2026Review
- Autoimmune-like hepatitis induced by drugs: Still many unanswered questions.World journal of hepatology · 2025Review
- Identification of key immune genes of drug-induced liver injury induced by tolvaptan based on bioinformatics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Integrated Analysis of Serum and Fecal Metabolites Reveals the Role of Bile Acid Metabolism in Drug-induced Liver Injury: Implications for Diagnostic and Prognostic Biomarkers.Journal of clinical and translational hepatology · 2025Article
- Unmet needs in autoimmune liver diseases.Current opinion in immunology · 2025Review
- The Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients.Drug safety · 2025Article
- Clinicopathological characteristics of autoimmune‑like hepatitis after drug‑induced liver injury.Biomedical reports · 2025Article
- Drug-Induced Liver Injury Caused by Metamizole: Identification of a Characteristic Injury Pattern.Liver international : official journal of the International Association for the Study of the Liver · 2025Observational
- Mechanisms and aetiology-dependent treatment of acute liver failure.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Methods for causality assessment of idiosyncratic drug-induced liver injury.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Efficient analysis of drug interactions in liver injury: a retrospective study leveraging natural language processing and machine learning.BMC medical research methodology · 2024Article
- Impact of Traditional Chinese Medicine Antioxidants on Oxidative Stress and Drug-Induced Liver Injury: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Interpretable multitemporal liver function indicator model for prediction and risk factor analysis of drug induced liver injury.Scientific reports · 2024Article
- The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 6 countries.
Funding
Abstract
BACKGROUND &
aimsNo multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported.
methodsPatients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016-2021. DILI cases or non-DILI acute liver injury controls following causality assessment were enrolled.
resultsOf 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis (n = 42) and viral hepatitis (n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre-existing liver disease. DILI cases and non-DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin-clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug-induced autoimmune-like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver-related death), and another six received liver transplantation.
conclusionsIn this first multi-national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.